Episodios

  • S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

    S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
    Jun 23 2025
    Episode Description

    In this podcast, ALS expert Terry Heiman-Patterson, MD, discusses best practices for ALS diagnosis and use of targeted therapy.

    Learning Objectives

    Upon successful completion of this activity, you should be better prepared to:

    • Apply recommended diagnostic criteria and strategies to make an early, accurate diagnosis of ALS
    • Discuss the mechanisms of action, efficacy, and safety of approved and emerging treatments for patients with ALS

    Acknowledgment of Educational Grant Support

    This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

    Instructions on How to Receive Credit

    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: XXXX
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.
    You may immediately download your certificate.
    Chair:

    Terry Heiman-Patterson, MD

    Professor, Neurology, Lewis Katz School of Medicine at Temple University
    Director, Temple MDA/ALS Center of Hope
    Philadelphia, PA

    Faculty, Staff, and Planners’ Disclosures

    In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.

    Release Date

    June 30, 2025
    Expiration Date

    Jun 30, 2026

    Off-Label Disclosure and Disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
    Más Menos
    26 m
  • S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

    S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)
    Jun 23 2025
    Episode Description

    In this podcast, ALS expert clinician-researcher Richard Bedlack MD, PhD, discusses targeted therapy for ALS and the role of individualized, multidisciplinary care to optimize patient outcomes.

    Learning Objectives

    Upon successful completion of this activity, you should be better prepared to:

    • Discuss the mechanisms of action, efficacy, and safety of approved and emerging treatments for patients with ALS
    • Develop individualized, multidisciplinary ALS management plans in collaboration with the patient and caregiver
    Acknowledgment of Educational Grant Support

    This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

    Instructions on How to Receive Credit

    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: XXXX
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.

    You may immediately download your certificate.

    Chair:

    Richard Bedlack, MD, PhD

    Stewart, Hughes, and Wendt Distinguished Professor
    Director of ALS Program
    Duke University Department of Neurology
    Durham, NC

    Disclosures: Consultant: AB Science, Advarra, ALS Association, Amylyx, Biogen Idec, Capvision, CareSpace Health, ClearView, Compassionate Care ALS, Eikonoklastes, Guidepoint Global, Health Advances, Health Care Strategy Partners, Ionis Pharmaceuticals, Kaplan, KeyQuest, Med-IQ, NeuroSense, Novartis, Prime Education, PTC Therapeutics, Roon; Research Support: Healey Center, MediciNova; Advisory Board: GenieUs; Other: Biogen, Ionis, NeuroSense, PTC.
    Faculty, Staff, and Planners’ Disclosures
    In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.
    Release Date

    June 30, 2025

    Expiration Date

    June 30, 2026

    Off-Label Disclosure and Disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
    Más Menos
    25 m
  • S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs

    S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs
    Jun 20 2025
    Episode Description
    In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they delve into emerging clinical data on next-generation, HER2-selective tyrosine kinase inhibitors. Through expert insights and discussion of recent trial findings, this conversation highlights how novel targeted therapies are reshaping treatment strategies and providing new hope for patients with HER2-mutant NSCLC.

    Acknowledgment of Educational Grant Support
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Catalyst Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corporation; Janssen Biotech, Inc; and Partner Therapeutics, Inc.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

    Instructions on How to Receive Credit
    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: 3462
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.

    You may immediately download your certificate.

    Today’s faculty are:

    Millie Das, MD
    Chief, Oncology, VA Palo Alto Health Care System
    Clinical Professor, Stanford University
    Palo Alto, CA

    Disclosures: Grant/Research Support: CellSight, Genentech, Merck, Novartis, Varian; Consultant: AbbVie, Amgen (uncompensated), Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech (uncompensated), Gilead, Guardant, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme.

    Eric K. Singhi, MD
    Assistant Professor
    Department of General Oncology and Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Disclosures: Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Regeneron.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    Off-Label Disclosure and Disclaimer
    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

    Release Date
    June 20, 2025

    Expiration Date
    June 20, 2026
    Más Menos
    26 m
  • S2 Ep31: Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

    S2 Ep31: Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
    Jun 10 2025
    Episode Description
    In this podcast, experts Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO, and Fred Hirsch, MD, PhD, review the evolving treatment landscape for limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage (ES) SCLC, including a discussion of the latest strategies for managing common and severe treatment-related adverse events.

    Acknowledgment of Educational Grant Support
    This activity is supported by an educational grant from AstraZeneca.

    Accreditation/Credit Designation
    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

    Instructions on How to Receive Credit
    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: 3451
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.
    You may immediately download your certificate.

    Today's faculty are:

    Fred Hirsch, MD, PhD, FASCO
    Professor of Medicine and Pathology
    Ning Zhao Chair Professor in Lung Cancer
    Executive Director, Center for Thoracic Oncology
    Associate Director of Biomarker Discovery, Tisch Cancer Institute
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Disclosures: Advisory Board: AstraZeneca/Daiichi Sankyo, Agilent Technologies/Dako, Bristol Myers Squibb, Henlius/Fosun, Natera, Novartis Pharmaceuticals, Novocure, OncoHost

    Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
    Director of Precision Oncology
    Cincinnati Cancer Advisors
    Cincinnati, OH

    Disclosures: Consultant: Amgen, AstraZeneca, Pfizer; Speakers’ Bureau: Amgen, Astellas Pharma, AstraZeneca, GSK, Pfizer

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    Off-Label Disclosure and Disclaimer
    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

    Release Date: June 18, 2025

    Expiration Date: June 18, 2026
    Más Menos
    1 h y 5 m
  • S2 Ep30: Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

    S2 Ep30: Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer
    May 30 2025
    Episode Description
    This PER® Show Me Your Care Plan!™ featured podcast brings together two medical oncologists and an oncology nurse to discuss the latest advances in the management of platinum-resistant ovarian cancer (PROC). The expert panel reviews current and emerging therapies, with a special focus on the management of adverse events associated with mirvetuximab soravtansine (MIRV) and other novel agents. Designed for oncology nurses and the broader care team, this program provides practical insights for integrating new evidence-based strategies into clinical practice to optimize outcomes for patients with PROC.

    Acknowledgment of Educational Grant Support
    This activity is supported by educational grants from AbbVie Inc and Corcept Therapeutics, Incorporated.

    Accreditation/Credit Designation
    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

    Instructions on How to Receive Credit
    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: 6725
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.
    You may immediately download your certificate.

    Today's faculty are:

    Ritu Salani, MD, MBA
    Professor, Department of Obstetrics and Gynecology
    Director, Gynecologic Oncology
    David Geffen School of Medicine at UCLA
    University of California, Los Angeles
    Los Angeles, CA

    Disclosures: Consultant: Daiichi Sankyo; Advisory Board: AbbVie, Eisai, GSK, Merck, Pfizer, Regeneron

    Emely Alfaro, MS, RN, CNS, OCN
    Assistant Clinical Professor
    UCSF School of Nursing
    Clinical Nurse Specialist, Outpatient Adult Oncology
    Adult Infusion Services
    San Francisco, CA

    Disclosures: Emely Alfaro, MS, RN, CNS, OCN, has no relevant financial relationships with ineligible companies.

    Jill Alldredge, MD
    Assistant Professor
    Division of Gynecologic Oncology
    University of Colorado
    Denver, CO

    Disclosures: Jill Alldredge, MD, has no relevant financial relationships with ineligible companies.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    Off-Label Disclosure and Disclaimer
    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

    Release Date: May 30, 2025

    Expiration Date: May 30, 2026
    Más Menos
    1 h y 26 m
  • S2 Ep29: Oncology PER® Spectives™: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

    S2 Ep29: Oncology PER® Spectives™: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
    Feb 28 2025
    30 m
  • S2 Ep28: Oncology PER® Spectives™: Oncology Consultations®: Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

    S2 Ep28: Oncology PER® Spectives™: Oncology Consultations®: Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
    Feb 3 2025
    30 m
  • S2 Ep27: Oncology PER® Spectives™: Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision Making and Future Therapies

    S2 Ep27: Oncology PER® Spectives™: Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision Making and Future Therapies
    Jan 28 2025
    52 m
adbl_web_global_use_to_activate_webcro805_stickypopup